The effects of formoterol on the serum, peritoneal VEGF, MDA, and VEGF levels in the ovaries and endometrium of rats with OHSS
| Autor: | Z.H. Ozturk Inal, Ayla Sargın Oruç, Müberra Namlı Kalem, N. Yilmaz, O. Han, Hakan Timur, Hasan Ali Inal |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Agonist
medicine.medical_specialty business.industry medicine.drug_class Peritoneal fluid Obstetrics and Gynecology Ovarian hyperstimulation syndrome Pregnant Mare Serum Gonadotropin Endometrium medicine.disease Malondialdehyde Placebo chemistry.chemical_compound Endocrinology medicine.anatomical_structure Reproductive Medicine chemistry Internal medicine medicine Formoterol business medicine.drug |
| Zdroj: | Clinical and Experimental Obstetrics & Gynecology. 44:122-128 |
| ISSN: | 0390-6663 |
| Popis: | PURPOSE To investigate the effects of formoterol (a beta2-adrenoreceptor agonist) on serum and peritoneal fluid VEGF, malondialdehyde (MDA) levels, and on VEGF-stained cell counts in the ovaries and endometrium of rats with ovarian hyperstimulation syndrome (OHSS) within the framework of immunohistochemical analysis. MATERIALS AND METHODS A total of 28 immature female Wistar rats were randomly divided into four groups. Three groups were given ten IU pregnant mare serum gonadotropin/day on days 22-25 of life. They were administered 30 IU hCG on day 26 of life to mimic OHSS. On days 26 and 27 of life, 24 mcg/kg/day formoterol in group 3 and 48 mcg/kg formoterol in group 4 were administered intraperitoneally per animal. RESULTS Although, there were no statistically significant differences between the groups in terms of serum and peritoneal fluid VEGF or MDA levels (serum VEGF: p = 0.28 1, peritoneal VEGF: p = 0.674, serum MDA: p = 0.543, peritoneal MDA: p = 0.506), there was a significant difference between the control and the OHSS placebo groups (p = 0.013) regarding the VEGF in the ovarian cortex. There was a significant difference between the control and the other groups in terms of ovarian stroma (p = 0.001), and there was also a statistically significant difference between the OHSS placebo and the other groups regarding VEGF in the endometrium (OHSS placebo vs. control group p = 0.002, OHSS placebo vs. the formoterol 24 mcg/kg group, p = 0.008, and OHSS-placebo vs. the formoterol 48 mcg/kg group, p = 0.001). CONCLUSIONS Formoterol represents a potential novel strategy for the management of OHSS. Further studies, including those examining the dosage of formoterol, are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|